{"entity":{"id":"terremoto-biosciences","kind":"company","name":"Terremoto Biosciences","aka":["Terremoto Biosciences Inc."],"tldr":"Terremoto Biosciences makes tablets that block AKT1, a growth signal that is switched on in many breast and other cancers, while trying to avoid the side effects of blocking related proteins. Its lead drug, TER-2013, is in an early trial.","summary":"Terremoto Biosciences Inc., based in South San Francisco and San Diego, California, designs small molecules using lysine-targeted covalent chemistry. Its lead oncology programme TER-2013 is an AKT1-selective inhibitor for solid tumours with alterations in PIK3CA, AKT or PTEN; in May 2026 the company announced FDA Fast Track designation for TER-2013 in HR-positive, HER2-negative breast cancer with these alterations after endocrine and CDK4/6 inhibitor therapy. A second programme, TER-4480, targets hereditary haemorrhagic telangiectasia. In April 2026 it closed a USD 108 million Series C with new investors RA Capital Management, Deep Track Capital, Osage University Partners and BeOne Medicines and existing investors OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant. Its first registered cancer trial, NCT07109726, a phase 1/2 study of TER-2013 alone and with fulvestrant in solid tumours harbouring AKT, PI3K or PTEN pathway alterations, including breast, endometrial, ovarian, cervical and squamous cancers of the lung, head and neck and oesophagus, was posted on ClinicalTrials.gov in August 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://terremotobio.com/"},{"label":"Series C release, April 2026","url":"https://terremotobio.com/press-release/terremoto-biosciences-closes-108-million-series-c-financing-to-advance-selective-akt1-inhibitors-in-oncology-and-hereditary-hemorrhagic-telangiectasia/"},{"label":"ClinicalTrials.gov: phase 1/2 trial of TER-2013 (NCT07109726)","url":"https://clinicaltrials.gov/study/NCT07109726"}],"tags":[],"related":[],"cancers":["breast-hr-positive","endometrial","ovarian","lung-squamous-cell-carcinoma","head-and-neck","oesophageal-squamous-cell-carcinoma","cervical"],"sections":["targeted-therapy"],"technologies":["pi3k-akt-mtor-inhibitors"],"targets":["akt","pik3ca","pten"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07109726"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website. The Series C release is dated 15 April 2026 in its text and listed under 2 June 2026 on the news page; the text date is used. The release names Charles Baum as chief executive; a later news headline announces James Christensen as chief executive. Earlier rounds were not read. Read on 29 October 2026."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://terremotobio.com/","stage":"growth","investors":["ra-capital","orbimed","third-rock-ventures","novo-holdings","cormorant-asset-management"],"funding":[{"round":"Series C","year":2026,"amountUsd":108000000,"source":"https://terremotobio.com/press-release/terremoto-biosciences-closes-108-million-series-c-financing-to-advance-selective-akt1-inhibitors-in-oncology-and-hereditary-hemorrhagic-telangiectasia/","note":"New investors RA Capital Management, Deep Track Capital, Osage University Partners and BeOne Medicines, with OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant"}]},"route":"/companies/terremoto-biosciences/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/"}],"target":[{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"},{"id":"pten","kind":"target","name":"PTEN","route":"/targets/pten/"}],"trial":[{"id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/"}],"company":[{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/"},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/"},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/"}]}}